Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania Using Electronic Device RebiSmart
Phase of Trial: Phase IV
Latest Information Update: 09 Dec 2018
Price : $35 *
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Demyelinating disorders; Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PROCEED
- Sponsors Merck KGaA
- 09 Mar 2017 Status changed from active, no longer recruiting to completed.
- 07 Dec 2015 Planned End Date changed from 1 Apr 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
- 07 Dec 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.